United Kingdom
Contact Us Careers
Select a Region
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
safety
Suvaxyn® PRRS MLV:
no significant increase in rectal temperature5
early vaccination is not detrimental to average daily gain5
NO significant injection site reactions5
Reference 5. Study Report No. B826C-GB-13-202, Zoetis Inc
Suvaxyn® PRRS MLV:
no negative impact on reproductive performance6
no significant increase in rectal temperatures6
no significant injection site reactions6
Reference 5. Study Report No. B826C-GB-13-202, Zoetis Inc
Select a Region
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
